Endo Buys Rights to Testosterone Replacement Gel

Endo Pharmaceuticals signed an agreement valued at up to $200 million with ProStrakan Group for the exclusive rights to commercialize Fortesta, a testosterone replacement gel, in the United States.
Philadelphia Business Journal